This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Ventas Q3 FFO and Revenues Beat Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR posts strong Q3 results with higher FFO and revenues, fueled by gains in senior housing and outpatient medical portfolios.
Ventas (VTR) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Ventas (VTR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ventas (VTR) Q3 FFO and Revenues Top Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of +1.15% and +3.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Federal Realty to Report Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
FRT is poised for third-quarter growth as demand for premium retail assets and mixed-use developments boosts revenues.
VICI Properties to Report Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
VICI's Q3 performance is set to benefit from stable lease revenues, portfolio diversification and steady growth across key income streams.
Invitation Homes to Report Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
INVH's Q3 results are likely to reflect strong demand for single-family rentals and tech-driven margin gains amid supply pressures.
What's in the Offing for Ventas Stock This Earnings Season?
by Zacks Equity Research
While VTR's Q3 earnings are likely to have benefited from SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.
UDR Set to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
UDR's diversified portfolio and tech upgrades are set to lift Q3 performance, though rising rental supply may have tempered gains.
PSA Set to Report Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
Public Storage's Q3 growth is expected to stem from technology-driven efficiencies and economies of scale, boosting revenues and FFO.
Extra Space Storage to Report Q3 Earnings: What to Expect?
by Zacks Equity Research
EXR's Q3 report may show solid revenue growth, but rising competition and discounting could pressure its margins and FFO.
Healthpeak Q3 FFO Beats Estimates, Same-Store NOI Rises Y/Y
by Zacks Equity Research
DOC's third-quarter results reflect the continued strong performance of its high-quality outpatient medical and CCRC portfolios.
American Tower to Report Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
AMT's Q3 revenues are likely to have risen on 5G rollout, cloud growth and macro-tower investments, though AFFO per share may have slightly dipped.
Welltower Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
WELL's Q3 results are likely to shine on the increasing aging population and its healthcare expenditure, though high interest expenses could weigh on gains.
BXP to Post Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
BXP's focus on high-quality and life science office conversions is likely to have lifted Q3 leasing, while debt and higher interest costs may weigh on results.
Alexandria to Post Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
ARE's Q3 results may show lower revenues and FFO as occupancy pressures weigh on performance.
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q3 earnings are likely to be hurt by lower revenues and higher interest expenses amid an aging population.
What's in Store for Crown Castle Stock This Earnings Season?
by Zacks Equity Research
Customer concentration and high interest expenses are likely to impact CCI's Q3 results despite its unmatched portfolio of wireless communication infrastructure assets.
Digital Realty to Post Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
DLR's vast data center network and AI-focused growth are set to drive a 6.4% revenue gain in Q3 2025.
Ventas (VTR) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Ventas Stock Rallies 16.3% Year to Date: Will the Trend Last?
by Zacks Equity Research
VTR's diverse healthcare portfolio, senior housing growth and strong liquidity fuel a 16.3% stock surge year to date.
Why Ventas (VTR) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Why Ventas (VTR) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Ventas Stock Gains 15.5% Year to Date: Will It Continue to Rise?
by Zacks Equity Research
VTR stock rallies 15.5% YTD as strong SHOP growth, accretive investments and a solid balance sheet fuel momentum.
Here's Why You Should Retain Welltower Stock in Your Portfolio Now
by Zacks Equity Research
WELL's seniors housing operating portfolio is set to benefit from the aging population and rising healthcare spending. However, high competition is a concern.